Signaling through Ras Is Essential for retOncogene-induced Cell Differentiation in PC12 Cells
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Specific germline mutations of the receptor tyrosine kinase, Ret, predispose to multiple endocrine neoplasia types 2A and 2B and familial medullary thyroid carcinoma. The mechanisms by which different Ret isoforms (Ret-2A and Ret-2B) cause distinct neoplastic diseases remain largely unknown. On the other hand, forced expression of these mutated versions of Ret induces the rat pheochromocytoma cell line, PC12, to differentiate. Here we used an inducible vector encoding a dominant-negative Ras (Ras p21(N17)) to investigate the contributions of the Ras pathway to the phenotype induced in PC12 cells by the expression of either Ret-2A or Ret-2B mutants. We show that the Ret-induced molecular and morphological changes are both mediated by Ras-dependent pathways. However, even though inhibition of Ras activity was sufficient to revert Ret-induced differentiation, the kinetics of morphological reversion of the Ret-2B- was more rapid than the Ret-2A-transfected cells. Further, we show that in Ret-transfected cells the suc1-associated neurotrophic factor-induced tyrosine phosphorylation target, SNT, is chronically phosphorylated in tyrosine residues, and associates with the Sos substrate. These results indicate the activation of the Ras cascade as an essential pathway triggered by the chronic active Ret mutants in PC12 cells. Moreover, our data indicate SNT as a substrate for both Ret mutants, which might mediate the activation of this cascade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![FIG. 2 Ras is required for expression of Krox-24 and vgf genes and for ERK kinase activity. A , Northern blot analysis of total cellular RNA (20 m g/lane) obtained from PC12 and PC12 variant cells as indicated: parental PC12, either untreated or stimulated for 5 h with NGF (100 ng/ml) as indicated; PC12/MEN2A-cl.3 ( MEN2A ); PC12/MEN2A N17 -cl.R1 ( MEN2A N17 ); PC12/MEN2B-cl.7 ( MEN2B ); PC12/MEN2B N17 -cl.R2 ( MEN2B N17 ) were treated for 6 h either with vehicle ( 2 ) or with dexamethasone (0.5 m M) ( 1 ), as indicated ( DEX ). The same filters were hybridized with either a Krox-24 -specific or vgf -specific probe as indicated, and equal gel loading was confirmed with a ribosomal 18 S probe. B , the cells and the treatment were the same as in A (except for NGF stimulation that lasted for 10 min). The cell lysates were immunoprecipitated with anti-ERK-1 antibody and assayed for kinase activity as described under 'Experimental Procedures.' In each experiment we verified that the same amounts of ERK were used in the kinase assay. Proteins from each of the immunoprecipitates were separated on 11% SDS-PAGE and immunoblotted with the same anti-ERK-1 antibody. Immunoblots confirmed that the same amount of ERK was used in each kinase assay (data not shown). The results shown were typical and representative of two independent experiments. C , PC12 cells were transfected with p Krox-24 -CAT (2 m g) together with pRet9 C634Y (0.6 m g) or pRet9 M918T (0.6 m g). Where indicated, cells were also cotransfected with increasing amount of the pZipN17 expressing the Ras p21 N17 mutant. The inhibition, calculated as the difference between the CAT activity in the absence and in the presence of pZipN17, is plotted as percentage relative to the induction observed in the absence of pZipN17. Results were from a representative experiment, and they were confirmed in two independent experiments each performed in duplicate. D , PC12 variant cells were transfected with p vgf -CAT (2 m g) together with either the pBabe Ha-Ras or the pBabe vector (8 m g), as indicated. Where indicated, dexamethasone was added 5 h after transfection. Results are expressed as percentage of conversion to acetylated [ 14 C]chloramphenicol.](https://figures.cochat.ai/paper-figures/e091d8b3ce304a9ca633a6e4ed90242a/signaling-through-ras-is-essential-for-retoncogene-induced-cell-differentiation-figure-2.png)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two prototype genes of Cluster 2 (RET and NF1) are linked by their common ability to activate the RAS/RAF/MAP kinase signaling cascade [16,17].”
From A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas (2005) · cites this paper as [17]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Marshall, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90401-8 · Cited by 3,906
Signaling Through Scaffold, Anchoring, and Adaptor Proteins
Pawson, T., & Scott, J. D. (1997) · Science · doi:10.1126/science.278.5346.2075 · Cited by 2,256
cAMP Activates MAP Kinase and Elk-1 through a B-Raf- and Rap1-Dependent Pathway
Vossler, M. R., Yao, H., York, R. D., Pan, M.-G., Rim, C. S., & Stork, P. J. S. (1997) · Cell · doi:10.1016/s0092-8674(00)80184-1 · Cited by 1,046
Intracellular Signaling Pathways Activated by Neuropathic Factors
Segal, R. A., & Greenberg, M. E. (1996) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.19.030196.002335 · Cited by 951
Kouhara, H., Hadari, Y. R., Spivak-Kroizman, T., Schilling, J., Bar-Sagi, D., Lax, I., & Schlessinger, J. (1997) · Cell · doi:10.1016/s0092-8674(00)80252-4 · Cited by 873
Activation of RET as a Dominant Transforming Gene by Germline Mutations of MEN2A and MEN2B
Santoro, M., Carlomagno, F., Romano, A., Bottaro, D. P., Dathan, N. A., Grieco, M., Fusco, A., Vecchio, G., Matoskova, B., Kraus, M. H., et al. (1995) · Science · doi:10.1126/science.7824936 · Cited by 841
Self-citationHagag, N., Halegoua, S., & Viola, M. (1986) · Nature · doi:10.1038/319680a0 · Cited by 412
Mechanism of Activation of the ret Proto-oncogene by Multiple Endocrine Neoplasia 2A Mutations
Asai, N., Iwashita, T., Matsuyama, M., & Takahashi, M. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.3.1613 · Cited by 340
Effect of a dominant inhibitory Ha-ras mutation on neuronal differentiation of PC12 cells.
Szeberényi, J., Cai, H., & Cooper, G. M. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.10.5324 · Cited by 322
Tsuzuki, T., Takahashi, M., Asai, N., Iwashita, T., Matsuyama, M., & Asai, J. (1995) · PubMed · Cited by 225
Research works printed but not linked: 12
- Tsuzuki, T., Takahashi, M., Asai, M., Iwashita, T., Matsuyama, M., and Asai, J. (1995) Oncogene 10, 191-198
- Colucci-D' Amato, G. L., D' Alessio, A., Filliatreau, G., Florio, T., Di Giamberardino, L., Chiappetta, G., Vecchio, G., Fusco, A., Santoro, M., and de Franciscis, V. (1996) Cell Growth Diff. 7, 1081-1086
- Borrello, M. G., Smith, D. P., Pasini, B., Bongarzone, I., Greco, A., Lorenzo, M. J., Arighi, E., Miranda, C., Eng, C., Alberti, L., Bocciardi, R., Mondellini, P., Scopsi, L., Romeo, G., Ponder, B. A. J., and Pierotti, M. A. (1995) Oncogene 11, 2419 -2417
- D' Arcangelo, G., and Halegoua, S. (1993) Mol. Cell. Biol. 13, 3146 -3155
- Califano, D., Monaco, C., De Vita, G., D'Alessio, A., Dathan, N. A., Possenti, R., Vecchio, G., Fusco, A., Santoro, M., and de Franciscis, V. (1995) Oncogene 11, 107-112
- D'Alessio, A., De Vita, G., Cali, G., Nitsch, L., Fusco, A., Vecchio, G., Santelli, G., Santoro, M., and de Franciscis, V. (1995) Cell Growth Diff. 6, 1387-1394
- Tahira, T., Ishizaka, Y., Itoh, F., Sugimura, T., and Nagao, M. (1990) Oncogene 5, 97-102
- van Weering, D. H., Medema, J. P., van Puijenbroek, A., Burgering, B. M., Baas, P. D., and Bos, J. L. (1995) Oncogene 11, 2207-2214
- Rabin, S. J., Cleghon, V., and Kaplan, D. R. (1993) Mol. Cell. Biol. 13, 2203-2213
- Wang, J. K., Xu, H., Li, H. C., and Goldfarb, M. (1996) Oncogene 13, 721-729
- Feig, L. A., and Cooper, G. M. (1988) Mol. Cell. Biol. 8, 2472-2478
- Szeberenyi, J., Cai, H., and Cooper, G. M. (1990) Mol. Cell. Biol. 10, 5324 -5332
Cited by
The GDNF/RET signaling pathway and human diseases
Takahashi, M. (2001) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00012-0 · Cited by 446
“[103] Califano D, Rizzo C, D’Alessio A, Colucci-D’Amato GL, Calı̀ G, Bartoli PC, et al.”
BackgroundA HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas
Dahia, P. L. M., Ross, K. N., Wright, M. E., Hayashida, C. Y., Santagata, S., Barontini, M., Kung, A. L., Sanso, G., Powers, J. F., Tischler, A. S., et al. (2005) · PLoS Genetics · doi:10.1371/journal.pgen.0010008 · Cited by 443
Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas
Welander, J., Söderkvist, P., & Gimm, O. (2011) · Endocrine-Related Cancer · doi:10.1530/erc-11-0170 · Cited by 355
“Oncogenic activation of RET triggers an activation of the RAS/RAF/MAPK pathway (Besset et al. 2000, Califano et al. 2000) and has also been associated with activation of the PI3K/AKT signaling pathway (Besset et al. 2000, Segouffin-Cariou & Billaud 2000).”
BackgroundNew Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification
Crona, J., Taïeb, D., & Pacak, K. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00062 · Cited by 324
The RET proto-oncogene in human cancers
Jhiang, S. M. (2000) · Oncogene · doi:10.1038/sj.onc.1203857 · Cited by 298
“Among these signaling pathways, signaling through Ras has been determined to be essential for RET-induced cell di erentiation in PC12 cells (Califano et al., 2000).”
BackgroundMultiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis
Hansford, J. R., & Mulligan, L. M. (2000) · Journal of Medical Genetics · doi:10.1136/jmg.37.11.817 · Cited by 241
Vasko, V, Saji, M., Hardy, E., Kruhlak, M., Larin, A., Savchenko, V, Miyakawa, M., Isozaki, O., Murakami, H., Tsushima, T., et al. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2003.015339 · Cited by 211
Ichihara, M. (2004) · Cancer Letters · doi:10.1016/s0304-3835(03)00456-7 · Cited by 197
Chronic activation of ERK and neurodegenerative diseases
Colucci‐D'Amato, L., Perrone‐Capano, C., & di Porzio, U. (2003) · BioEssays · doi:10.1002/bies.10355 · Cited by 195
“However, in theseconditionsERKfails toefficiently translocate into the nucleus, as shown by the lack of transcription activation of immediate early genes (IEG), such as c-fos Nevertheless, nuclear phospho-ERK can be detected and it is probably accountable for the basal transcription levels of some IEG.”
BackgroundHypoxia-Inducible Factor Signaling in Pheochromocytoma: Turning the Rudder in the Right Direction
Jochmanova, I., Yang, C., Zhuang, Z., & Pacak, K. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt201 · Cited by 172
Crona, J., Verdugo, A. D., Maharjan, R., Stalberg, P. L. H., Granberg, D. O., Hellman, P., & Björklund, P. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4257 · Cited by 160
Parenti, G., Zampetti, B., Rapizzi, E., Ercolino, T., Giaché, V., & Mannelli, M. (2012) · Journal of Oncology · doi:10.1155/2012/872713 · Cited by 138
Kurokawa, K., Iwashita, T., Murakami, H., Hayashi, H., Kawai, K., & Takahashi, M. (2001) · Oncogene · doi:10.1038/sj.onc.1204290 · Cited by 121
“Califano et al. (2000) recently reported that RET with MEN2 mutations interacted with SNT/FRS2.”
BackgroundVolk, H., Potschka, H., & Löscher, W. (2005) · Journal of Histochemistry & Cytochemistry · doi:10.1369/jhc.4a6451.2005 · Cited by 109
“…antibody H241 (Santa Cruz Biotechnology, Inc.; Santa Cruz, CA), which was raised against a recombinant protein corresponding to amino acids 1040–1280 mapping at the P-gp C-terminal cytoplasmic domain, recognizes P-gp of human, mouse, and rat origin (Califano et al. 2000; Weisberg and Griffin 2000).”
BackgroundA Drosophila Model of Multiple Endocrine Neoplasia Type 2
Read, R. D., Goodfellow, P. J., Mardis, E. R., Novak, N., Armstrong, J. R., & Cagan, R. L. (2005) · Genetics · doi:10.1534/genetics.104.038018 · Cited by 94
“…and oncogenic Ret leads to recruitment of the Shc, SNT/FRS2, and Grb2 adaptor proteins to mediate Ras activation and induction of ERK signaling (van Weering et al. 1995; Ohiwa et al. 1997; Chiariello et al. 1998; Califano et al. 2000; Hayashi et al. 2000; Kurokawa et al. 2001; Melillo et al. 2001).”
BackgroundInfluentialThe Genetics of Neuroendocrine Tumors
Öberg, K. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.11.005 · Cited by 75
Functional Analysis of RET With Hirschsprung Mutations Affecting Its Kinase Domain
Iwashita, T., Kurokawa, K., Qiao, S., Murakami, H., Asai, N., Kawai, K., HASHIMOTO, M., Watanabe, T., Ichihara, M., & Takahashi, M. (2001) · Gastroenterology · doi:10.1053/gast.2001.25515 · Cited by 75
Murakumo, Y., Jijiwa, M., Asai, N., Ichihara, M., & Takahashi, M. (2006) · Pituitary · doi:10.1007/s11102-006-0263-4 · Cited by 75
Cyclooxygenase-2 Expression in Thyroid Nodules
Specht, M. C., Tucker, O., Hocever, M., Gonzalez, D., Teng, L., & Fahey, T. J. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.1.8179 · Cited by 74
Evolving concepts in pheochromocytoma and paraganglioma
Dahia, P. L. (2006) · Current Opinion in Oncology · doi:10.1097/01.cco.0000198017.45982.06 · Cited by 69
Signaling Pathways in Pheochromocytomas and Paragangliomas: Prospects for Future Therapies
Nölting, S., & Grossman, A. B. (2012) · Endocrine Pathology · doi:10.1007/s12022-012-9199-6 · Cited by 68
MANAGEMENT OF ENDOCRINE DISEASE: Clinical management of paragangliomas
Corssmit, E. P. M., & Romijn, J. A. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0396 · Cited by 67
Precision medicine in pheochromocytoma and paraganglioma: current and future concepts
Björklund, P., Pacák, K., & Crona, J. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12507 · Cited by 67
Conservation of RET proto-oncogene splicing variants and implications for RET isoform function
Carter, M. T., Yome, J. L., Marcil, M. N., Martin, C. A., Vanhorne, J. B., & Mulligan, L. M. (2001) · Cytogenetic and Genome Research · doi:10.1159/000059341 · Cited by 67
Gentile, M. T., Ciniglia, C., Reccia, M. G., Volpicelli, F., Gatti, M., Thellung, S., Florio, T., Melone, M. A. B., & Colucci-D’Amato, L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118864 · Cited by 66
Miyagi, E., Braga‐Basaria, M., Hardy, E., Vasko, V. V., Burman, K. D., Jhiang, S. M., Saji, M., & Ringel, M. D. (2004) · Molecular Carcinogenesis · doi:10.1002/mc.20042 · Cited by 57
Singh, R. S., Singh, T., & Singh, A. K. (2019) · Elsevier eBooks · doi:10.1016/b978-0-444-64114-4.00009-1 · Cited by 50
Molecular markers of paragangliomas/pheochromocytomas
Zhikrivetskaya, S. O., Snezhkina, A. V., Zaretsky, A. R., Alekseev, B. Y., Pokrovsky, A. V., Golovyuk, A. L., Melnikova, N. V., Stepanov, O. A., Kalinin, D. V., Moskalev, A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15201 · Cited by 45
“Furthermore, uncontrolled activation of the RAS/ RAF/ERK pathway is observed in paragangliomas/ pheochromocytomas with mutations in the RET and NF1 genes [161-163] (Figure 2).”
BackgroundThe RET Receptor Is Linked to Stress Response Pathways
Myers, S. M., & Mulligan, L. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3605 · Cited by 41
“EGR1 Early growth response protein 1 1.16 0.673 (44, 48, 49, 50) CXCL12 Chemokine ligand 12, stromal cell-derived factor 1 precursor 1.09 0.067 (46) GJA1 Gap junction protein, 1, 43 kDa (connexin 43) 1.08 0.835 ( 52 ) PTN Pleiotrophin precursor 1.06 0.900 (46) PLOD2 Procollagen-lysine, 2-oxoglutarate 5-dioxygenase (ly…”
InfluentialColucci-D'Amato, G. L., D'Alessio, A., Califano, D., Calı̀, G., Rizzo, C., Nitsch, L., Santelli, G., & de Franciscis, V. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.25.19306 · Cited by 37
Self-citationGenetics of Pheochromocytomas and Paragangliomas Determine the Therapeutical Approach
Sarkadi, B., Saskői, É., Butz, H., & Patócs, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031450 · Cited by 37
Rapizzi, E., Ercolino, T., Fucci, R., Zampetti, B., Felici, R., Guasti, D., Morandi, A., Giannoni, E., Giaché, V., Bani, D., et al. (2014) · Hormones and Cancer · doi:10.1007/s12672-014-0172-3 · Cited by 32
“On the other hand, RET- and NF1-mutated PGLs are associated with abnormal activation of RAS/RAF/MAPK and PI3K/AKT/mTOR intracellular pathways, involved in cell proliferation and differentiation [28, 29].”
BackgroundLiberto, V. D., Mudò, G., & Belluardo, N. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.05.006 · Cited by 31
“, 1999a, 1999b) and it is required for GDNF-mediated differentiation and survival of neurons (Coulpier et al., 2002; Califano et al., 2000; De Vita et al., 2000; Asai et al., 1996; Besset et al., 2000) As extension of previous work (Battaglia et al.”
Influentialde Bresser, C. J. M., & de Krijger, R. R. (2024) · Endocrine Pathology · doi:10.1007/s12022-024-09830-3 · Cited by 27
Carbajo, D., Magi, S., Itoh, M., Kawaji, H., Lassmann, T., Arner, E., Forrest, A. R. R., Carninci, P., Hayashizaki, Y., Daub, C. O., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144176 · Cited by 26
“for the PC-12 cell line, stimulation of the cells by nerve growth factor (NGF) induces differentiation, while stimulation by epidermal growth factor (EGF) induces proliferation [5].”
BackgroundAndrew, S. D., Capes‐Davis, A., Delhanty, P. J. D., Marsh, D. J., Mulligan, L. M., & Robinson, B. G. (2002) · Gene · doi:10.1016/s0378-1119(02)00919-8 · Cited by 21
Hadoux, J., Desterke, C., Féraud, O., Guibert, M., Rose, R. F. D., Opolon, P., Divers, D., Gobbo, E., Griscelli, F., Schlumberger, M. J., et al. (2017) · Stem Cell Research · doi:10.1016/j.scr.2017.11.015 · Cited by 21
The Tyrosine Phosphatase Shp-2 Mediates Intracellular Signaling Initiated by Ret Mutants
D’Alessio, A. M., Califano, D., Incoronato, M., Santelli, G., Florio, T., Schettini, G., Carlomagno, M. S., Cerchia, L., & de Franciscis, V. (2003) · Endocrinology · doi:10.1210/en.2003-0620 · Cited by 19
Self-citationRET fusion in advanced non-small-cell lung cancer and response to cabozantinib: A case report
Wang, Y., Xu, Y., Wang, X., Sun, C., Guo, Y., Shao, G., Yang, Z., Qiu, S., & Ma, K. (2019) · Medicine · doi:10.1097/md.0000000000014120 · Cited by 18
“Activation of RET protein can activate several signaling pathways, including those of mitogen activated protein kinase (MAPK), phosphoinositide 3-kinase (PI3K)/AKT, Rac/c-jun NH, kinase (JNK), phospholipase C-g, and Ras/mitogen-activated protein (MAP) kinase (also known as ERK).([9,10]) Normally, RET is essential for…”
BackgroundManuvakhova, M., Thottassery, J. V., Hays, S., Qu, Z., Rentz, S. S., Westbrook, L., & Kern, F. G. (2006) · Oncogene · doi:10.1038/sj.onc.1209592 · Cited by 18
“The PTB domain of SNT-1 also binds to the RET receptor tyrosine kinase that is activated by glial cell line derived factor (GDNF) or multiple endocrine neoplasia (MEN) 2 mutations (Califano et al., 2000; Kurokawa et al., 2001).”
BackgroundCyclooxygenase-2 expression and its association with thyroid lesions
Krawczyk‐Rusiecka, K., & Lewiñski, A. (2010) · Archives of Medical Science · doi:10.5114/aoms.2010.17076 · Cited by 18
“It can be expressed in response to various stimuli, such as hormones, mitogens, cytokines, other inflammatory mediators and growth factors via protein kinase C and Ras-mediated signalling [12, 13].”
BackgroundIncoronato, M., D’Alessio, A., Paladino, S., Zurzolo, C., Carlomagno, M. S., Cerchia, L., & de Franciscis, V. (2004) · Cellular Signalling · doi:10.1016/j.cellsig.2004.01.002 · Cited by 17
Self-citationDíaz‐Rodriguez, E., Garcia-Rendueles, Á. R., Ibáñez‐Costa, A., Gutiérrez‐Pascual, E., García-Lavandeira, M., Leal, A., Japón, M. Á., Soto, A., Venegas, E., Tinahones, F. J., et al. (2014) · Endocrinology · doi:10.1210/en.2014-1034 · Cited by 16
Krawczyk‐Rusiecka, K., Wojciechowska-Durczyńska, K., Cyniak-Magierska, A., Adamczewski, Z., Gałecka, E., & Lewiñski, A. (2011) · Thyroid Research · doi:10.1186/1756-6614-4-3 · Cited by 12
“COX-2 can be expressed in response to various stimuli, such as hormones, mitogens, cytokines, inflammatory mediators and growth factors via protein kinase C and RAS-mediated signaling [3,4].”
BackgroundAngiogenesis and Multiple Sclerosis Pathogenesis: A Glance at New Pharmaceutical Approaches
Gentile, M., Muto, G., Lus, G., Lövblad, K., Svenningsen, Å., & Colucci-D'Amato, L. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164643 · Cited by 5
Genetics of pheochromocytoma and paraganglioma
Benn, D. E., Marsh, D. J., & Robinson, B. G. (2002) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/00060793-200202000-00010 · Cited by 9
Uçan, B., Özbek, M., Şahin, M., Kızılgül, M., & Çakal, E. (2017) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-1708-49 · Cited by 6
Neurocristopathies and Particular Associations with Hirschsprung’s Disease
Moore, S. W. (2007) · Springer eBooks · doi:10.1007/978-3-540-33935-9_18 · Cited by 4
Genetic markers for the diagnosis and prognosis of pheochromocytoma
Thouënnon, E., Pierre, A., Guillemot, J., Yon, L., Eisenhofer, G., & Anouar, Y. (2009) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.4.1.45 · Cited by 3
Genetic Alterations in Pheochromocytoma and Paraganglioma
Welander, J. (2015) · Linköping University medical dissertations · doi:10.3384/diss.diva-114806 · Cited by 2
Paraganglioma and Pheochromocytoma
Iacobone, M., & Torresan, F. (2021) · Springer eBooks · doi:10.1007/978-3-030-62241-1_15 · Cited by 2
Cremaschi, V., Laganà, M., Turla, A., Dondi, F., Trevisan, B., Giacchè, M., Grisanti, S., Zilioli, V., Bertagna, F., Berruti, A., et al. (2026) · Endocrine · doi:10.1007/s12020-025-04525-z · Cited by 1
The GDNF Family: From Neurotrophic Factors to Oncogenesis
Poteryaev, D. A., & Saarma, M. (2001) · Molecular Biology · doi:10.1023/a:1010447703347 · Cited by 1
Mannelli, M., Parenti, G., Canu, L., Filpo, G. D., & Rapizzi, E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65796-3 · Cited by 1
Non-neuronal roles for GDNF and novel GDNF family receptors
Lindahl, M. (2004) · Työväentutkimus Vuosikirja · Cited by 1
Structure and function of GDNF receptor alpha splice variants
Yang, J. (2006) · Helda - University of Helsinki Institutional Repository
Pheochromocytoma and Paraganglioma
Corssmit, E. P. M., & van Hulsteijn, L. T. (2015) · Springer eBooks · doi:10.1007/978-3-662-45215-8_24
Lower vagal tone associated with anxiety disorders in women with irritable bowel syndrome
Jarrett, M. E., Burr, R. L., Cain, K. C., Hertig, V. L., & Heitkemper, M. M. (2001) · Gastroenterology · doi:10.1016/s0016-5085(01)83170-x
New Perspectives on Diagnostics, Prognosis, and Therapy in Aggressive Endocrine Tumours
Appetecchia, M., Wolffenbuttel, B. H. R., & AlJadir, S. J. (2012) · Journal of Oncology · doi:10.1155/2012/820938
INVESTIGATING THE RELATIONSHIP BETWEEN THE RET RECEPTOR, CBL, AND ARHGEF7 IN DOWNREGULATION OF RET
Kaur, H. (2008) · QSpace (Queen's University Library)
RET RECEPTOR ACTIVATION TARGETS EXPRESSION OF THE PLEIOTROPIC CYTOKINE INTERLEUKIN-11
Zhu, S. (2015) · QSpace (Queen's University Library)
GDNF FAMILY RECEPTORS IN PERIPHERAL TARGET INNERVATION AND HORMONE PRODUCTION
Lindfors, P. H. (2006) · Helda - University of Helsinki Institutional Repository
Fine-mapping of the gene responsible for a new variant of multiple endocrine neoplasia in the rat
Piotrowska, K. (2005) · mediaTUM (Technical University of Munich)
Skull Base Tumors: Viewpoint—Fractionated Radiotherapy or Stereotactic Radiotherapy
Mirimanoff, R., & Negretti, L. (2015) · Springer eBooks · doi:10.1007/978-1-4614-8363-2_40
[Research Progress of Fusion Genes RET in Non-small Cell Lung Cancer].
Zheng, Y. G., Jiang, W., Chen, D., Li, Y., Dai, L., Huang, L., & Wang, M. (2021) · PubMed Central · doi:10.3779/j.issn.1009-3419.2021.102.22
Paraganglioma and Pheochromocytoma
Sandberg, A. A. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-510-7_5
Mannelli, M., Parenti, G., Canu, L., Filpo, G. D., & Rapizzi, E. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00131-x
Hereditary cancer syndromes linked to oxidative phosphorylation insufficiency
Kaplan, B., Duraj, T., Lee, D. C., & Seyfried, T. N. (2025) · ONCOLOGIE · doi:10.1515/oncologie-2025-0301
Caractérisation moléculaire des formes métastatiques de carcinome médullaire de la thyroïde
Boichard, A. (2014) · theses.fr (ABES) · doi:10.70675/f53a0a06z97fbz4f07z8659zeb4ee22bd0b5
Charting the Genetic Landscape and Clonal Architectures of Pheochromocytoma
Crona, J. (2014) · DiVA (Digitala Vetenskapliga Arkivet)
Metadata
- Authors
- Califano, D., Rizzo, C., D'Alessio, A., Colucci-D'Amato, G. L., Calı̀, G., Bartoli, P. C., Santelli, G., Vecchio, G., & de Franciscis, V.
- Affiliations
- Institute for Experimental Endocrinology and Oncology (IT)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2000-06
- Volume
- 275
- Issue
- 25
- Pages
- 19297-19305
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2045078390
- Cited by
- 67
- References
- 39
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2022: 2 · 2021: 1 · 2019: 2 · 2018: 1 · 2017: 4 · 2016: 1 · 2015: 6 · 2014: 4 · 2013: 3 · 2012: 3
- FWCI
- 1.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 7432 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, cc-by)
- Funders
- Fondazione Telethon
- Consiglio Nazionale delle Ricerche
- Associazione Italiana per la Ricerca sul Cancro
- National Institutes of Health (MD 20892)
- Fogarty International Center
- Center for Advanced Study, University of Illinois at Urbana-Champaign
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Health Sciences › Medicine › Clinical Neurology › Neurofibromatosis and Schwannoma Cases
- Keywords
- RET receptor tyrosine kinase, Ras signaling, PC12 cells, neuronal differentiation, dominant negative Ras, multiple endocrine neoplasia type 2, medullary thyroid carcinoma, SO, tyrosine phosphorylation
- MeSH terms
- Animals, Cell Differentiation, Membrane Proteins, Neurons, Oncogenes, Phosphoproteins, Phosphorylation, Proto-Oncogene Proteins, Tyrosine, Signal Transduction, Oncogene Protein p21(ras), PC12 Cells, Receptor Protein-Tyrosine Kinases, Drosophila Proteins, Adaptor Proteins, Signal Transducing, Proto-Oncogene Proteins c-ret, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.